Is FURX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

263 people get FURX articles and Market Currents by email alert.

Get email alerts on FURX »

HEADLINES:

Furiex Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Furiex Reports First Quarter 2013 Financial Results

Business Wire (May 7, 2013)
Furiex Pharmaceuticals Announces First Quarter 2013 Earnings Release and Conference Call

Business Wire (Apr 9, 2013)
Furiex Pharmaceuticals to Receive Milestone Payment for Priligy® Launch in France

Business Wire (Apr 4, 2013)
Furiex Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7
Furiex Reports Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Mar 6, 2013)
Best Performing U.S. Stocks YTD Through February
Bespoke Investment Group • Fri, Mar 1 • 2 Comments
Furiex Pharmaceuticals to Present at Cowen & Company 33rd Annual Healthcare Conference

Business Wire (Feb 26, 2013)
Furiex Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. Food and Drug Administration for Avarofloxacin (JNJ-Q2)

Business Wire (Feb 25, 2013)
3 Attractively Valued Biotechs From BIO CEO 2013
Brian L. Wilson • Thu, Feb 14
Best-Performing Russell 3000 Stocks Year To Date
Bespoke Investment Group • Mon, Feb 11
Furiex Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Earnings Release and Conference Call

Business Wire (Jan 29, 2013)
Monday Options Brief: PETM, FURX & SPLS
Interactive Brokers • Mon, Jan 28
Furiex Confirms Takeda’s Receipt of FDA Approval of NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the Treatment of Type 2 Diabetes

Business Wire (Jan 25, 2013)
Furiex Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 2, 2012
Furiex Reports Third Quarter 2012 Financial Results

Business Wire (Nov 1, 2012)
Furiex Pharmaceuticals Announces Third Quarter 2012 Earnings Release and Conference Call

Business Wire (Oct 1, 2012)
5 Pharmaceutical Companies With Insider Buying During August 14-16
Markus Aarnio • Sun, Aug 19, 2012 • 6 Comments
Insider Trades: Opportunity Or Sham?
Brian Mundy • Sun, Aug 19, 2012 • 2 Comments
Furiex Reports Second Quarter 2012 Financial Results

Business Wire (Aug 2, 2012)

To learn more about Seeking Alpha Pro, click here.

Major Insider Buying And Diversified Pipeline Has Me Interested In This Speculative Drug Stock
Bret Jensen • Sun, Jul 29, 2012 • 1 Comment
Closer Look: Furiex's Big Bounce
Brian L. Wilson • Wed, Jul 11, 2012
Is Furiex Due For A Bounce?
Brian L. Wilson • Tue, Apr 17, 2012
Furiex Pharmaceutical's Coming Events Could Boost Stock Price
Roy Manning III • Mon, Mar 26, 2012 • 4 Comments
Heavy Activity For Furiex Pharmaceuticals In 2012
Brian L. Wilson • Mon, Jan 23, 2012
Furiex Pharmaceuticals Breaks Downtrend As Insiders Buy In Big
M. E. Garza • Thu, Nov 10, 2011

Best Performing U.S. Stocks YTD Through February
Bespoke Investment Group • Fri, Mar 1 • 2 Comments
3 Attractively Valued Biotechs From BIO CEO 2013
Brian L. Wilson • Thu, Feb 14
Best-Performing Russell 3000 Stocks Year To Date
Bespoke Investment Group • Mon, Feb 11
Monday Options Brief: PETM, FURX & SPLS
Interactive Brokers • Mon, Jan 28
5 Pharmaceutical Companies With Insider Buying During August 14-16
Markus Aarnio • Sun, Aug 19, 2012 • 6 Comments
Insider Trades: Opportunity Or Sham?
Brian Mundy • Sun, Aug 19, 2012 • 2 Comments
7 Highly Liquid Insider Stock Picks Reporting Earnings Next Week
Kapitall • Thu, Jul 26, 2012
IPO Preview: Durata Therapeutics
IPOdesktop • Wed, Jul 18, 2012
Notable Micro Cap Insider Buys This Week
Gutone • Sun, Jun 24, 2012 • 1 Comment
Notable Micro Cap Insider Buys Last Week
Gutone • Sat, Jun 9, 2012 • 4 Comments
$1,000,000 Worth Of Insider Buys Last Week
Gutone • Tue, Jun 5, 2012 • 1 Comment
5 Insider Stock Picks On Winning Streaks
Kapitall • Sun, Jun 3, 2012
Notable Micro Cap Insider Buys Last Week
Gutone • Mon, May 28, 2012 • 4 Comments
Tracking David Einhorn's Greenlight Capital Portfolio - Q1 2012 Update
John Vincent • Mon, May 21, 2012 • 6 Comments
3 Outperforming Small Caps Bought Up By Insiders And Hedge Funds
Kapitall • Fri, Apr 13, 2012 • 1 Comment
9 Healthcare Stocks With Major Catalysts Due in April
Spencer Knight • Mon, Apr 2, 2012 • 8 Comments
Bio Tech Stocks With Huge Upside Or Downside Potential In April
StockPandit • Thu, Mar 29, 2012
Insider Buys And Sells: Sohu, Tesla
Asif Suria • Mon, Mar 19, 2012 • 1 Comment
Insider Buys And Sells: Corning, Cabela's
Asif Suria • Mon, Mar 12, 2012
Tracking David Einhorn's Portfolio - Q4 2011 Update
John Vincent • Fri, Feb 17, 2012

Furiex Reports First Quarter 2013 Financial Results

Business Wire (May 7, 2013)
Furiex Pharmaceuticals Announces First Quarter 2013 Earnings Release and Conference Call

Business Wire (Apr 9, 2013)
Furiex Pharmaceuticals to Receive Milestone Payment for Priligy® Launch in France

Business Wire (Apr 4, 2013)
Furiex Reports Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Mar 6, 2013)
Furiex Pharmaceuticals to Present at Cowen & Company 33rd Annual Healthcare Conference

Business Wire (Feb 26, 2013)
Furiex Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. Food and Drug Administration for Avarofloxacin (JNJ-Q2)

Business Wire (Feb 25, 2013)
Furiex Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Earnings Release and Conference Call

Business Wire (Jan 29, 2013)
Movers & Shakers: Monday’s movers: Herbalife clobbered on FTC news

at MarketWatch.com (Jan 28, 2013)
Furiex Confirms Takeda’s Receipt of FDA Approval of NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the Treatment of Type 2 Diabetes

Business Wire (Jan 25, 2013)
Furiex Reports Third Quarter 2012 Financial Results

Business Wire (Nov 1, 2012)
Furiex Pharmaceuticals Announces Third Quarter 2012 Earnings Release and Conference Call

Business Wire (Oct 1, 2012)
Health Care Sector Wrap

at Fox Business (Aug 24, 2012)
Health Care Sector Wrap

at Fox Business (Aug 24, 2012)
Health Care Sector Wrap

at Fox Business (Aug 24, 2012)
Health Care Sector Wrap

at Fox Business (Aug 24, 2012)
Health Care Sector Wrap

at Fox Business (Aug 24, 2012)
Furiex Reports Second Quarter 2012 Financial Results

Business Wire (Aug 2, 2012)
Furiex Pharmaceuticals Amends Current Loan and Security Agreement, Adding an Additional $30.0 Million

Business Wire (Aug 2, 2012)
Furiex Pharmaceuticals Announces Closing of Priligy® Asset Transfer and License Agreements

Business Wire (Jul 30, 2012)
Furiex Confirms Takeda’s Resubmissions of Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone NDAs to the U.S. FDA

Business Wire (Jul 27, 2012)

FURX vs. ETF Alternatives

Company Description

We are a drug development collaboration company that uses innovative, clinical development strategies to increase the value of partnered pharmaceutical assets and accelerate their development timelines. We collaborate with pharmaceutical and biotechnology companies to increase the value of their... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 7, 4:52 PM Furiex Pharmaceuticals (FURX): Q1 EPS of $0.82 misses by $0.19. Revenue of $39.3M beats by $5.88M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, April 4, 3:03 PM Furiex Pharmaceuticals (FURX -1%) slips today, in spite of its earlier announcement of a $5M milestone payment from the Menarini Group for the launch of Priligy in France. The drug is currently marketed by FURX in 16 countries in Europe, Asia and Latin America, and is approved in 56 countries worldwide. Under the it's agreement with Menarini, FURX is eligible to receive up to $40M in sales-based milestones, plus tiered royalties ranging from the mid-teens to mid-twenties in percentage terms. Comment! [Healthcare, Global & FX, On the Move]
Wednesday, March 6, 4:31 PM Furiex (FURX): Q4 EPS of -$0.90 beats by $0.98. Revenue of $9.21M beats by $1.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, January 28, 12:45 PM Midday top 10 gainers: KERX +79%. FURX +51%. SHIP +39%. CTC +18%. HGSH +17%. SINO +14%. RSH +12%. CPBC +11%. OCZ +11%. ACAD +10%.
Midday top 10 Losers: NVGN -61%. RPRX -27%. JOSB -18%. TRMD -16%. BYFC -15%. JVA -12%. DDD -11%. PRCP -10%. SSYS -9%. AKS -8%. Comment! [On the Move]
Monday, January 28, 9:10 AM Premarket gainers: FURX +49%. KERX +46%. NTE +14%. SNE +7%. DOLE +7%. HES +6%. GGC +6%. ACAD +5%.
Losers: JOSB -17%. MTG -5%.
Comment! [On the Move]
Monday, January 28, 8:11 AM Furiex Pharmaceuticals (FURX) extends its late Friday rally, moving up another 27.2% premarket on the strength of the news that the company could be in line for a milestone payment tied to a diabetes drug. 3 Comments [Healthcare, On the Move]
Friday, July 27, 2012, 4:18 PM Furiex Pharmaceuticals (FURX +5.5%) ramped higher into the close after confirming that Takeda Pharmaceutical (TKPYY.PK) has resubmitted New Drug Applications to the FDA for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for treating adult type 2 diabetes. Under it's agreement with Takeda, FURX is eligible to receive a $25M milestone payment for the approval of the first of these two NDAs, as well as additonal royalties and sales-based milestones. Comment! [Healthcare, Global & FX, On the Move]
Tuesday, May 15, 2012, 1:50 PM Johnson & Johnson's (JNJ +0.5%) subsidiary Alza Corp. and Janssen Pharmaceutica NV agree to transfer world-wide rights for the premature ejaculation treatment Priligy to drug developer Furiex Pharmaceuticals (FURX +9.3%). Comment! [Healthcare, Global & FX, On the Move]
Thursday, April 26, 2012, 9:20 AM Premarket gainers: PATK +26%. HTWR +15%. REGN +14%. NUAN +14%. LOGI +14%. VHC +12%. CTXS +12%. NRGY +10%. EQIX +9%. CRUS +8%. SPPI +8%. INCY +7%. XLNX +7%. WPI +7%. AMRN +5%. EA +7%. MWW +5%. AH +6%. PHM +6%. AIS +5%. AIXG +5%. LSI +4%. TS +3%. UN +3%. ZNGA +3%. FRO +3%. RDS +3%.
Losers: FURX -28%. PCS -15%. HRB -15%. TQNT -14%. ALU -13%. TSPT -12%. AET -9%. PTX -7%. AKAM -6%. AZN -6%. ZMH -5%. DB -5%. HERO -5%. STD -5%. DOW -4%. CELG -4%. CS -4%. CROX -4%. GG -3%. BWA -3%. UNH -3%. LVS -3%. VALE -3%. UPS -3%. POT -3%. Comment! [On the Move]
Thursday, April 26, 2012, 8:36 AM Furiex Pharmaceuticals (FURX) -27% premarket after the company says the FDA requested further data from partner Takeda Pharmaceutical (TKPYY.PK) regarding the new drug applications for alogliptin and the fixed-dose combination therapy alogliptin and pioglitazone. Comment! [Healthcare, On the Move]
Thursday, December 8, 2011, 5:20 PM Furiex Pharmaceuticals (FURX) announces its PPD-10558 drug for treating statin-associated myalgia "did not meet its primary efficacy endpoint" during Phase II trials. As a result, Furiex will discontinue further development work on PPD-10558. Shares are currently halted. Comment! [Healthcare, On the Move]
Wednesday, November 23, 2011, 11:23 AM Four companies that recently saw insider buying: Coca-Cola (KO - 100K shares purchased by a director), Flowserve (FLS - 7K shares purchased by its CEO), 8x8 (EGHT - 41.5K shares purchased by a director), and Furiex Pharmaceuticals (FURX - 265K shares purchased by a director, and 6.2K shares purchased by its CFO). Comment! [Quick Ideas]

FURX Furiex Pharmaceuticals, Inc.

FURX

Furiex Pharmaceuticals, Inc.